Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.77 |
| ▸ | TRPM2 | O94759 | 5/20 | 0.68 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.63 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783845 | 1.00 | TRPA1 (0.77) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL6786045 | 0.90 | TRPA1 (0.61) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL6786038 | 0.90 | TRPA1 (0.61) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL4021693 | 0.90 | TRPM2 (0.69) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL29966683 | 0.90 | TRPM2 (0.69) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL6786753 | 0.89 | DHODH (0.65) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL6786747 | 0.89 | DHODH (0.65) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL2780698 | 0.87 | TRPA1 (1.00) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL2780699 | 0.87 | TRPA1 (1.00) | TRPA1TRPM2LTB4RTRPM8MEN1 | |
| SCHEMBL6780675 | 0.87 | ALDH1A1 (0.60) | TRPA1TRPM2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727250-B2 | ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-04-27 | — | — | US | disclosed |
| CN-1414849-A | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGECHEIM PHARMA KG (DE) | 2003-04-30 | — | — | CN | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | TRPA1 4750/4885TRPM2 4819/4885LTB4R 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.